Organisation paid for research Program year 2025 Source: CMS Open Payments

The Trustees of Columbia University

Neither a doctor nor a teaching hospital

Research payments

$22,065,749

1,505 payments

Through program year 2025, The Trustees of Columbia University is reported as receiving $22,065,749 in research payments, across 1,505 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,804,911	355
2024	Research	$3,847,347	191
2023	Research	$3,324,538	237
2022	Research	$3,305,266	181
2021	Research	$2,272,458	183
2020	Research	$1,591,309	157
2019	Research	$2,919,919	201

Breakdown

Who paid Research payments · program years 2019–2025

Edwards Lifesciences Corporation $7,386,623 660 payments
Ipsen Biopharmaceuticals, Inc $1,880,030 11 payments
Pfizer Inc. $1,833,233 22 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $1,765,413 88 payments
Janssen Research & Development, LLC $952,629 15 payments
Merck Sharp & Dohme Corporation $883,544 7 payments
AbbVie, Inc. $873,943 91 payments
Biogen, Inc. $816,894 10 payments
Novartis Pharmaceuticals Corporation $687,826 6 payments
Genzyme Corporation $579,594 3 payments

Studies the money was for Research payments · program years 2019–2025

Partner3 2015-08 $935,531 66 payments
Alliance 2021-05 $908,430 18 payments
Exploratory Phase II Study of Lanreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) $822,108 5 payments
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody)Combined with JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer $812,042 7 payments
TRISCEND II Pivotal (2020-05) $761,490 24 payments
Big City Concept Collaboration $725,546 2 payments
CLASP II TR Pivotal, Study No. 2019-07 $563,079 30 payments
Gtx-102-Cl301 $526,866 7 payments
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy $474,658 2 payments
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. $453,540 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.